Effect of depression and serotonin reuptake inhibitors antidepressant treatment during pregnancy on protein expression in the human placenta: A quantitative proteomics analysis
Einfluss von Depression und Serotonin-Wiederaufnahmehemmern in der Schwangerschaft auf die Proteinexpression in der menschlichen Plazenta: quantitative Proteomik-Analyse
PLOS One · 11.12.2025 · 20 (12) · e0322090
DOI: 10.1371/journal.pone.0322090 ↗Auf einen Blick
Bei 82 Schwangeren wurden Plazenten proteomisch untersucht. Depression ohne SRI war mit veränderten Proteinmustern verbunden; unter SRI-Behandlung zeigten sich geringere Veränderungen in Richtung Seneszenz, Amyloidbildung und Plättchenaktivierung.
Fragestellung
Wie beeinflussen Depression und eine SRI-Antidepressivabehandlung in der Schwangerschaft das Plazentaproteom?
Methode
Quantitative Shotgun-Proteomik mit LC-MS/MS in einer Kohorte von Schwangeren im 2. Trimenon; HAM-D zur Gruppeneinteilung in nicht-depressiv, depressiv/ohne SRI und depressiv/mit SRI.
Ergebnisse
Im Vergleich zu gesunden Personen zeigte die Gruppe depressiv/ohne SRI mehr antioxidative Enzyme und SASP-Proteine sowie weniger Histonproteine. Gegenüber depressiv/ohne SRI war in der SRI-Gruppe eine Herunterregulation von Proteinen zu Seneszenz, Amyloidbildung und Plättchenaktivierung zu sehen.
Einschränkungen
Weitere Studien sind nötig, um die Befunde zu bestätigen.
Schlussfolgerung der Autor:innen
Die Autor:innen schließen, dass eine SRI-Behandlung die bei antenataler Depression beobachteten Plazentaveränderungen wie Seneszenz, Plättchenaktivierung und Amyloidbildung abschwächen könnte.
Kernaussagen
- 82 Schwangere wurden im 2. Trimenon eingeschlossen
- Depression ohne SRI: mehr antioxidative Enzyme und SASP-Proteine
- Unter SRI: weniger Proteine zu Seneszenz, Amyloidbildung und Plättchenaktivierung
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 11.12.2025. Verfasst von Linda Ok und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institut national de la recherche scientifique (INRS) - Centre Armand-Frappier Santé Biotechnologie, Laval, Quebec, Canada. Hauptthemen laut MEDLINE: Placenta, Selective Serotonin Reuptake Inhibitors, Depression, Antidepressive Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Canadian Institutes of Health Research.
Themen: Depression
Abstract (Originalsprache)
Depression is one of the most prevalent mental health disorders affecting pregnant individuals, and serotonin reuptake inhibitors (SRIs) are the most prescribed medications to treat depressive symptoms during pregnancy. Both depression and SRI exposure may have developmental impacts, and as randomizing exposures and non-treatment is not feasible in humans, distinguishing the effect of each factor often remains challenging. To date, much of what guides clinical practice stems from reports of pregnant individuals and fetal/infant outcomes, overlooking the significant role of the placenta in maintaining a healthy pregnancy and mother-fetal health. In this study, we explored the effect of depression and SRI antidepressant treatment during pregnancy on the placental proteome. A shotgun proteomics method with liquid chromatography and tandem mass spectrometry (LC-MS/MS) was performed. A cohort of pregnant individuals (n = 82) was recruited in their 2 nd trimester, and clinician-rated mood symptoms measured using the Hamilton Depression Rating Scale (HAM-D) were obtained from them during pregnancy to identify three exposure groups: non-depressed; depressed/non-SRI-treated; depressed/SRI-treated. Differential protein expression and over-representation analyses on the placentas of the group with depression/non-SRI compared with placentas from healthy individuals showed an increase in antioxidant enzymes and various senescence-associated secretory phenotypes (SASP) as well as a decrease in histone proteins. Such protein expression patterns are potentially indicative of placental senescence. Our findings reveal that depression not treated with SRIs is associated with the upregulation of proteins involved in platelet activation, degranulation, coagulation cascade, and amyloid fiber formation in the placenta. In contrast, when comparing placentas from the depressed group treated with SRIs to those with depressive symptoms without SRI treatment, we observed a downregulation of proteins related to senescence, amyloid fiber formation, and platelet activation in the SRI-treated group. This study suggests that treatment with SRIs may prevent the placental alterations observed in antenatal depression, such as placental senescence, platelet activation, and amyloid fiber formation, and, ultimately, pregnancy and fetal outcomes. Further studies are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institut national de la recherche scientifique (INRS) - Centre Armand-Frappier Santé Biotechnologie, Laval, Quebec, Canada.
- Research Centre and CIUSSS du Nord-de-l'Île-de-Montréal, Montréal, Quebec, Canada.
- Chemistry Department/CERMO-FC, Université du Québec à Montréal, Montréal, Quebec, Canada.
- Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
- BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
- Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
ORCID-Profile: Linda Ok, Kayleigh S J Campbell, Lekha Sleno, Cathy Vaillancourt
Förderung
- NICHD NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Canadian Institutes of Health Research
Zitieren
APA
Ok, L., Ohlund, L., Inkster, A. M., Campbell, K. S. J., Peñaherrera, M. S., Brain, U., Sleno, L., Robinson, W. P., Barry, A., Oberlander, T. F., & Vaillancourt, C. (2025). Effect of depression and serotonin reuptake inhibitors antidepressant treatment during pregnancy on protein expression in the human placenta: A quantitative proteomics analysis. PLOS One, 20(12), e0322090. https://doi.org/10.1371/journal.pone.0322090
Vancouver
Ok L, Ohlund L, Inkster AM, Campbell KSJ, Peñaherrera MS, Brain U, et al. Effect of depression and serotonin reuptake inhibitors antidepressant treatment during pregnancy on protein expression in the human placenta: A quantitative proteomics analysis. PLOS One. 2025;20(12):e0322090. doi:10.1371/journal.pone.0322090
BibTeX
@article{Ok2025,
author = {Ok, Linda and Ohlund, Leanne and Inkster, Amy M and Campbell, Kayleigh S J and Peñaherrera, Maria S and Brain, Ursula and Sleno, Lekha and Robinson, Wendy P and Barry, Amadou and Oberlander, Tim F and Vaillancourt, Cathy},
title = {Effect of depression and serotonin reuptake inhibitors antidepressant treatment during pregnancy on protein expression in the human placenta: A quantitative proteomics analysis},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {12},
pages = {e0322090},
doi = {10.1371/journal.pone.0322090}
}
EUVIMED